Ziessman H A, Bahar H, Fahey F H, Dubiansky V
J Nucl Med. 1987 Sep;28(9):1408-11.
This study examines the frequency and significance of diffuse liver uptake on 131I whole-body thyroid cancer scans. Sixty whole-body scans on 27 patients with differentiated thyroid cancer were reviewed. Liver uptake was quantitated on another 21 studies (16 patients). Diffuse hepatic uptake was seen in 44% of patients and 35% of all the studies. It correlated best with the 131I dose administered (r = 0.733) and the product of the 131I percent radioactive iodine uptake (RAIU) and administered dose (r = 0.656), less well with the serum 131I protein bound iodine (r = 0.494) and the RAIU. This study demonstrates that liver visualization is more common than generally appreciated and is related to the 131I dose and indices of thyroid function although other factors may also play a role in liver visualization.
本研究探讨了¹³¹I全身甲状腺癌扫描中肝脏弥漫性摄取的频率及意义。回顾了27例分化型甲状腺癌患者的60次全身扫描。对另外21项研究(16例患者)的肝脏摄取进行了定量分析。44%的患者及35%的所有研究中可见肝脏弥漫性摄取。其与¹³¹I给药剂量相关性最佳(r = 0.733),与¹³¹I放射性碘摄取百分比(RAIU)与给药剂量的乘积相关性较好(r = 0.656),与血清¹³¹I蛋白结合碘(r = 0.494)及RAIU的相关性较差。本研究表明,肝脏显影比一般认为的更为常见,且与¹³¹I剂量及甲状腺功能指标相关,尽管其他因素在肝脏显影中可能也起作用。